Alexion Pharmaceuticals is a biopharmaceutical company that is committed to discovering, developing, and providing innovative treatments for patients suffering from severe and life-threatening diseases. The company focuses on rare and ultra-rare diseases and has made significant contributions to the medical industry. Uses Alexion Pharmaceuticals is best known for its drug Soliris. This drug is used to treat two rare and serious blood disorders called paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). PNH is a rare life-threatening disease that causes red blood cells to break down prematurely. aHUS is a rare genetic disorder that affects the kidneys, leading to damage and ultimately kidney failure. Dosage The dosage of Soliris is determined by a doctor and may vary depending on the patient's age, weight, sex, and medical condition. For patients with PNH, the recommended dose is 600 mg once a week for the first four weeks, followed by a maintenance dose of 900 mg once a week. For patients with aHUS, the recommended starting dose is 900 mg once weekly for the first four weeks, followed by a maintenance dose of 1,200 mg once every two weeks. Side Effects Like all medications, Soliris may have side effects. The most common side effects associated with Soliris include headache, nausea, fatigue, and back pain. Serious side effects may include serious allergic reactions, meningitis, and blood infections. If any of these symptoms occur, patients should contact their doctor immediately. Interactions Soliris may interact with other drugs or supplements. Patients should inform their doctor of all medications they are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. It is important to note that Soliris may reduce the effectiveness of vaccines. Generic As of now, there is no generic version of Soliris. The patent for Soliris expired in November 2020, but the company has exclusivity rights until 2027. Demographic Soliris is used in both adults and children. However, the drug is not recommended for patients with certain medical conditions, such as meningococcal infections, because it may increase their risk of serious infections. Patients should always consult their doctor to determine if Soliris is right for them. Conclusion Alexion Pharmaceuticals has made a significant contribution to the medical industry by developing innovative treatments for rare and ultra-rare diseases. Soliris is an effective treatment for PNH and aHUS, two rare and serious blood disorders. Patients should always consult their doctor to determine if Soliris is right for them and be aware of the potential side effects and interactions. However, the development of a generic version of Soliris is necessary to make it more accessible to those who need it.